Stocks Health care VCYT
NASDAQ · Health careVeracyte, Inc. (VCYT)
Veracyte, Inc. brought in $581.8M of revenue over the twelve months to September 30, 2026, up 17.5% from a year earlier. Net income was $126.8M, a net margin of 21.8%. Operating cash flow minus capital spending left $126.6M of free cash flow in fiscal 2025. At September 30, 2026 it held $199.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Veracyte, Inc.
- Net worth
- Veracyte, Inc. has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of $1.4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $517.1M (+16.0% year on year), with net income of $66.4M. Over the 12 months to September 30, 2026: revenue $581.8M, net income $126.8M.
- Cash flow
- In fiscal 2025 operations brought in $136.3M of cash; after $9.7M of capital spending, free cash flow was $126.6M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Veracyte, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Veracyte, Inc. does
Veracyte, Inc. is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker VCYT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $517.1M | $66.4M | $0.82 | $126.6M |
| 2024 | $445.8M | $24.1M | $0.31 | $63.8M |
| 2023 | $361.1M | -$74.4M | -$1.02 | $34.3M |
| 2022 | $296.5M | -$36.6M | -$0.51 | -$1M |
| 2021 | $219.5M | -$75.6M | -$1.11 | -$37M |
| 2020 | $117.5M | -$34.9M | -$0.66 | -$12.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VCYT ranks in Health care
Latest SEC filings
What Veracyte, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 15% to $151.8M versus the same quarter last year; diluted EPS $0.38 versus $0.24.
- November 4, 2026
- September 14, 2026
- July 31, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 15% to $150.3M versus the same quarter last year; diluted EPS $0.31 versus -$0.01.
- July 30, 2026
- June 11, 2026
- June 10, 2026
- June 5, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026Passive stake changed SCHEDULE 13G/A
What is VCYT worth? A DCF from its reported cash flow
Insider trades
What the people running Veracyte, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.9M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 28, 2026 | Wygant JonathanVP, Chief Accounting Officer | Shares withheld for tax | 1,306 | $65.7K |
| October 27, 2026 | Eastham KarinDirector | Exercised options | 10,000 | $270.1K |
| October 27, 2026 | Eastham KarinDirector | Soldpre-planned (10b5-1) | 14,850 | $742.6K |
| October 27, 2026 | Holstein JensDirector | Exercised options | 7,500 | $264.8K |
| October 27, 2026 | Holstein JensDirector | Soldpre-planned (10b5-1) | 7,500 | $375K |
| October 19, 2026 | Bhanji MunaDirector | Soldpre-planned (10b5-1) | 1,864 | $81.5K |
| September 24, 2026 | Holstein JensDirector | Exercised options | 7,500 | $264.8K |
| September 24, 2026 | Holstein JensDirector | Soldpre-planned (10b5-1) | 7,500 | $352.5K |
Who owns VCYT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 10.1% | June 5, 2026 |
| Artisan Partners Asset Management Inc.13G, passive with 3 related filers | 6.9% | May 13, 2026 |
| Artisan Partners Limited Partnership13G, passive with 3 related filers | 6.5% | November 12, 2024 |
| Vanguard Portfolio Management13G, passive | 5.67% | April 29, 2026 |
| Vanguard Capital Management13G, passive | 5.2% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 370 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 13,486,437 | +313,819 |
| Fmr LLC | 7,702,746 | -61,103 |
| Artisan Partners Limited Partnership | 5,538,404 | +42,034 |
| Vanguard Portfolio Management LLC | 4,716,191 | +271,461 |
| State Street Corp | 4,698,128 | -345,462 |
| Vanguard Capital Management LLC | 3,593,922 | +61,690 |
| Dimensional Fund Advisors LP | 2,826,524 | -54,566 |
| First Trust Advisors LP | 2,507,902 | +390,856 |
| ARK Investment Management LLC | 2,295,951 | -757,867 |
| Wellington Management Group Llp | 2,274,160 | -284,125 |
| Geode Capital Management, LLC | 2,104,000 | +146,904 |
| Goldman Sachs Group Inc | 1,642,911 | +366,651 |
| Fuller & Thaler Asset Management, Inc. | 1,509,749 | +95,387 |
| William Blair Investment Management, LLC | 1,431,596 | +441,909 |
| Morgan Stanley | 1,191,790 | +393,988 |
| Bank of America Corp | 1,102,279 | -346,618 |
| Driehaus Capital Management LLC | 1,045,826 | new |
| Northern Trust Corp | 996,154 | +66,654 |
| Charles Schwab Investment Management Inc | 939,983 | +16,410 |
| Oberweis Asset Management Inc/ | 877,734 | +37,900 |
Insiders
15 insiders reported holding 1,362,361 shares in total, about $32.9M at the last price.
| Holder | Shares |
|---|---|
| Stapley MarcChief Executive Officer, Director | 432,073 |
| Chambers RebeccaChief Financial Officer | 166,025 |
| Febbo Phillip G.Chief Scientific & Med Officer | 133,048 |
| McGuire AnnieEVP, General Counsel | 131,160 |
| Leite JohnGlobal Chief Commercial Off | 124,329 |
| Epstein Robert SDirector | 57,718 |
| Barr EliavDirector | 56,461 |
| Haas Kevin RichardChief Dev and Tech Officer | 44,221 |
| Wygant JonathanVP, Chief Accounting Officer | 41,920 |
| Bhanji MunaDirector | 40,854 |
Questions about VCYT
What does Veracyte, Inc. do?
Veracyte, Inc. is a company in the Health care sector, listed on NASDAQ as VCYT. Its shares trade on NASDAQ under the ticker VCYT.
What is Veracyte, Inc.'s net worth?
Veracyte, Inc. has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of $1.4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Veracyte, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $126.8M on revenue of $581.8M, a net margin of 21.8%.
How much revenue does Veracyte, Inc. make?
Over the twelve months to September 30, 2026 Veracyte, Inc. reported revenue of $581.8M. That is 17.5% more than a year earlier.
When did Veracyte, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Veracyte, Inc.'s next earnings report?
Veracyte, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VCYT with
Follow VCYT
Get an email when Veracyte, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Veracyte, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.